Follow Patrick on: XPhyto Therapeutics adds top-level executive talent to lead commercialization of its Covid-ID Lab Wolfgang Probst was named chief operations officer and Manfred Buchberger will head corporate development at German subsidiary XP Diagnostics GmbH Probst and Buchberger will be responsible for executing the global product launch and business development of Covid-ID Lab XPhyto Therapeutics Corp (CSE:XPHY) (OTCQB:XPHYF) (FRA:4XT) has announced the appointment of Wolfgang Probst as its chief operations officer and the addition of Manfred Buchberger as head of corporate development at XP Diagnostics GmbH, the company’s wholly-owned German subsidiary. With European CE-IVD approval announced last month for the company's lead diagnostic product Covid-ID Lab, XPhyto said it continues to enhance its commercial team as it anticipates near-term distribution and sales.